- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01668121
Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers (REFLI)
November 22, 2012 updated by: Orion Corporation, Orion Pharma
Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers, Two Batches of Symbicort Turbuhaler and Budesonide/Formoterol Easyhaler: Randomised, Double-blind, Double-dummy, Single Centre, Single Dose, Crossover Study in Healthy Subjects
The primary objective of this study is to evaluate the acceptance range with which two Symbicort Turbohaler batches could be declared bioequivalent in a bioequivalence setting.
The secondary objective is to compare pharmacokinetic parameters of the reference product batches and Budesonide/formoterol Easyhaler.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany
- Parexel International GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent (IC) obtained.
- Males and females, 18-55 (inclusive) years of age.
- Normal weight defined as body mass index (BMI) > 19 and < 30 kg/m2 (BMI= weight/height2).
- Weight at least 50 kg.
- Forced expiratory volume in one second (FEV1) at least 80% of the predicted value measured at the screening.
- Good general health ascertained by detailed medical history, and laboratory and physical examinations.
Exclusion Criteria:
- Vulnerable subjects (i.e. persons under any administrative or legal supervision).
- Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease within previous 2 years; or evidence of active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.
- Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. As an exception, paracetamol and ibuprofen for occasional pain are allowed.
- Intake of any medication that could affect the outcome of the study. As an exception, contraceptives and hormone replacement therapy are allowed. The use of medicines which are strong CYP3A4 inducers or inhibitors are restricted for at least 2 weeks prior to the first study treatment administration and during the study.
- Any clinically significant abnormal laboratory value or physical finding (including electrocardiogram [ECG] and vital signs) that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study, as judged by the investigator. More specifically, supine HR < 45 or > 100 bpm after 10-min rest or supine systolic BP >140 or < 90 or diastolic BP > 90 or < 60 mmHg after a 10-minute rest, or a QTc-Bazett (QTcB interval) > 450 msec at screening evaluation.
- Known hypersensitivity to the active substances or the excipient (lactose, which contains small amounts of milk protein) of the drug.
- History of vasovagal collapses.
- History of anaphylactic/anaphylactoid reactions.
- History of seizures including febrile seizures.
- Pregnant or lactating females.
- Females of childbearing potential if they are not using proper contraception (mechanical and/or hormonal contraception, intrauterine device [IUD] or surgical sterilization). Double method of contraception is needed when using oral or mechanical contraception: e.g. condom in conjunct with oral contraception and spermicidal product with mechanical contraception (please see section 5.7 for details).
- Recent or current (suspected) drug abuse or positive result in the drugs abuse test.
- Recent or current alcohol abuse (regular drinking more than 21 units per week for males and more than 16 units per week for females [1 unit = 4 cl spirits or equivalent]).
- Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day and/or inability to refrain from the use of nicotine containing products during the study (from the screening visit to the end-of-study visit).
- Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability to refrain from the use of caffeine containing beverages during the treatment periods until 24 h after study treatment administration.
- Blood donation or loss of significant amount of blood within 30 days prior to the first study treatment administration.
- Administration of another investigational drug within 30 days prior to the first study treatment administration.
- Unsuitable veins for repeated venepuncture or for cannulation.
- Inability to learn the correct inhalation technique.
- Predictable poor compliance or inability to communicate well with the study centre personnel.
- Inability to participate in all treatment periods.
- The subject is not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
- Positive result in HIV, hepatitis B or C tests.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Symbicort Turbohaler
|
|
ACTIVE_COMPARATOR: Budesonide/formoterol Easyhaler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameter Cmax of plasma Budesonide concentration
Time Frame: within 12 h
|
within 12 h
|
Pharmacokinetic parameter AUCt of plasma Budesonide concentration
Time Frame: within 12 h
|
within 12 h
|
Pharmacokinetic parameter Cmax of plasma Formoterol concentration
Time Frame: within 24 h
|
within 24 h
|
Pharmacokinetic parameter AUCt of plasma Formoterol concentration
Time Frame: within 24 h
|
within 24 h
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Merja Mäkitalo, Orion Corporation, Orion Pharma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (ACTUAL)
November 1, 2012
Study Completion (ACTUAL)
November 1, 2012
Study Registration Dates
First Submitted
August 15, 2012
First Submitted That Met QC Criteria
August 15, 2012
First Posted (ESTIMATE)
August 17, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
November 27, 2012
Last Update Submitted That Met QC Criteria
November 22, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Budesonide
- Formoterol Fumarate
- Budesonide, Formoterol Fumarate Drug Combination
Other Study ID Numbers
- 3103012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Symbicort Turbohaler
-
Istituto per la Ricerca e l'Innovazione BiomedicaCompleted
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.; University of Sydney; The University... and other collaboratorsCompleted
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary DiseaseChina
-
University Hospital, AntwerpAstraZenecaCompletedChronic Obstructive Pulmonary DiseaseBelgium
-
Mundipharma Research LimitedCompleted
-
Pearl Therapeutics, Inc.Completed
-
Zambon SpAFLUIDDA nvCompletedAsthma | Asthma Chronic | Asthmatic | Asthma BronchialBelgium
-
AstraZenecaCompletedCOPD PatientsUnited States, Spain, Bulgaria, Mexico, Poland, South Africa, Germany, Argentina, Chile, Czechia, Puerto Rico
-
Chiesi Farmaceutici S.p.A.TerminatedChronic Obstructive Pulmonary DiseaseNetherlands
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed